Background -The clinical benefit of the administration of aerosolised recombinant human DNase (rhDNase) on pulmonary function in patients with cystic fibrosis has already been demonstrated but the biochemical action of rhDNase on DNA in bronchial secretions in vivo has not yet been investigated. Methods -Sputum was collected from 135 patients with cystic fibrosis before and during treatment with aerosolised rhDNase and examined to ascertain DNA concentration and length by colorimetric assay and densitometry of gel separated DNA. Results -Treatment with rhDNase reduced the concentration and the size of extracellular DNA in the sputum. The median interquartile range of DNA length decreased from 0*5-2*6 kbp before treatment to 0-3-1P0 kbp during treatment. Conclusions -rhDNase was delivered to the secretions and was enzymatically active in vivo. (Thorax 1995;50:880-882) 
Respiratory tract disease characterised by the accumulation of mucopurulent secretions and chronic endobronchial infection is responsible for more than 90% of the morbidity and mortality in cystic fibrosis.' On the basis of the hypothesis that an increased concentration of high molecular weight DNA contributes to the abnormal viscoelastic properties of sputum and airway obstruction, recombinant human deoxyribonuclease I (rhDNase) has been delivered as an aerosol to the airways of patients with cystic fibrosis.2`7 The administration of rhDNase reduced but did not eliminate exacerbations of respiratory symptoms7 and resulted in a slight improvement in pulmonary function.'-7 Although the clinical benefit of aerosolised rhDNase has been demonstrated in several trials,"7 the biochemical action of rhDNase on its substrate in vivo has not yet been investigated. We measured the concentration and length of DNA in sputum samples from patients with cystic fibrosis collected before and during treatment with aerosolised rhDNase.
Methods
One hundred and thirty five patients with cystic fibrosis from seven German cystic fibrosis outpatient clinics participated in a 12 week phase III trial on the inhalation of 2 5 mg rhDNase (Pulmozyme, Genentech Inc, San Francisco, USA) once daily. Criteria for study entry were no indications for hospital admission and a forced vital capacity of 40-70% predicted.
Sputum expectorated during physiotherapy was collected on three consecutive days directly before the first inhalation ofrhDNase and again on three consecutive days after six weeks of inhalation of rhDNase. Sputum containers were stored in the refrigerator and at the end of each sampling period the three sputum containers were brought to the Hannover laboratory, frozen to -20°C upon arrival, and stored for up to six weeks. Thawed sputum was liquified for 3-5 hours at room temperature under stirring with a twofold volume of 2% (v/v) aqueous mercaptoethanol. Cells and debris were spun down by centrifugation at 1200 g for 10 minutes. Supematants from each patient's three day collection period were pooled and lyophilised, with the exception of the 63 pretreatment and 72 treatment samples from the 25 patients ofthe Hannover cystic fibrosis clinic which were analysed on a day-to-day basis. The freeze dried sample was reconstituted in distilled water and the DNA concentration was then determined by colorimetric assay with diphenylamine according to the method of Burton8 modified by Croft and Lubran9 using human blood cell DNA as standard. To determine the DNA length, DNA was isolatedl' from lyophilised samples by digestion with proteinase K, extractions with phenol/chloroform, precipitation with ethanol, and dissolution in 10 mM Tris/HCl, 1 mM EDTA, pH 8-0. The purified DNA was separated by 1% agarose gel electrophoresis using a X-BstEII digest as a size marker. The size distribution was measured by laser densitometry of 8-5 x 10-8 cm Polaroid negative films of the ethidium bromide-stained agarose gel.
Recombinant human DNase in cystic fibrosis
Median (interquartiles and range) concentration and length of extracellular DNA in sputum samples from patients with 'Yield of purified DNA was too low in eight pretreatment and 13 treatment samples to perform densitometry of gel separated DNA.
'Variance was only calculated if patients delivered two (2, 1 patients) or three (18, 23 patients) sputum containers.
The statistical significance of the rhDNase inhalation on DNA lengtl centration was evaluated with the M ney rank test. Aliquots of cystic fibro controls which were either immed cessed after collection or intermitte at -20°C for up to eight weeks gav results within experimental error.
Results
The DNA contents in sputum san 132 patients were analysed before t halation of rhDNase and from 12 after six weeks of inhalation of rhD extracellular DNA content in the spu from 0 to 9-5 mg/ml ( This study was performed in collaboration with the members of the "German Clinical Study Group on rhDNase" at the Roche company (Dr Deuber) and the cystic fibrosis clinics in Berlin (Dr Tacke), Essen (Dr Stephan), Frankfurt (Dr Posselt), Giei3en (Dr Lindemann), Halle (Dr Br6mme), Hannover (Dr Ballmann) and Musnchen (Drs Harms).
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